Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial
Sunil Bhandari, Philip A. Kalra, Mario Berkowitz, et al.
Nephrology Dialysis Transplantation (2020) Vol. 36, Iss. 1, pp. 111-120
Open Access | Times Cited: 87

Showing 1-25 of 87 citing articles:

Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference
Jodie L. Babitt, Michele F. Eisenga, Volker H. Haase, et al.
Kidney International (2021) Vol. 99, Iss. 6, pp. 1280-1295
Open Access | Times Cited: 165
Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside—a systematic review and meta‐analysis
Benedikt Schaefer, Moritz Tobiasch, André Viveiros, et al.
British Journal of Clinical Pharmacology (2020) Vol. 87, Iss. 5, pp. 2256-2273
Open Access | Times Cited: 94
Newer formulations of intravenous iron: a review of their chemistry and key safety aspects – hypersensitivity, hypophosphatemia, and cardiovascular safety
Irina Blumenstein, Satish Shanbhag, Peter Langguth, et al.
Expert Opinion on Drug Safety (2021) Vol. 20, Iss. 7, pp. 757-769
Open Access | Times Cited: 63
Serum Biomarkers of Iron Stores Are Associated with Increased Risk of All-Cause Mortality and Cardiovascular Events in Nondialysis CKD Patients, with or without Anemia
Murilo Guedes, Daniel G. Muenz, Jarcy Zee, et al.
Journal of the American Society of Nephrology (2021) Vol. 32, Iss. 8, pp. 2020-2030
Open Access | Times Cited: 60
Expert consensus guidelines: Intravenous iron uses, formulations, administration, and management of reactions
Layla Van Doren, Marlene M. Steinheiser, Kristen Boykin, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 7, pp. 1338-1348
Open Access | Times Cited: 12
Systematic Review of the Effects of Iron on Cardiovascular, Kidney and Safety Outcomes in Patients With Chronic Kidney Disease
Bernard Chan, Amanda Varghese, Sunil V. Badve, et al.
Kidney International Reports (2025) Vol. 10, Iss. 4, pp. 1037-1049
Open Access | Times Cited: 1
Intravenous iron supplementation therapy
Benedikt Schaefer, Eva Meindl, Sonja Wagner, et al.
Molecular Aspects of Medicine (2020) Vol. 75, pp. 100862-100862
Open Access | Times Cited: 67
Absolute and functional iron deficiency: Biomarkers, impact on immune system, and therapy
Marianela Iriarte‐Gahete, Laura Tarancón‐Díez, Vanesa Garrido‐Rodríguez, et al.
Blood Reviews (2024) Vol. 68, pp. 101227-101227
Closed Access | Times Cited: 8
Risk Factors for and Effects of Persistent and Severe Hypophosphatemia Following Ferric Carboxymaltose
Benedikt Schaefer, Heinz Zoller, Myles Wolf
The Journal of Clinical Endocrinology & Metabolism (2021) Vol. 107, Iss. 4, pp. 1009-1019
Open Access | Times Cited: 36
Recent and Emerging Therapies for Iron Deficiency in Anemia of CKD: A Review
Jonathan W. Bazeley, Jay B. Wish
American Journal of Kidney Diseases (2021) Vol. 79, Iss. 6, pp. 868-876
Open Access | Times Cited: 33
A systematic literature review and meta-analysis of the incidence of serious or severe hypersensitivity reactions after administration of ferric derisomaltose or ferric carboxymaltose
Nicholas A. Kennedy, Maureen M. Achebe, Patrick Biggar, et al.
International Journal of Clinical Pharmacy (2023) Vol. 45, Iss. 3, pp. 604-612
Open Access | Times Cited: 14
Clinical data for intravenous iron – debunking the hype around hypersensitivity
Maureen Achebe, Thomas G. DeLoughery
Transfusion (2020) Vol. 60, Iss. 6, pp. 1154-1159
Open Access | Times Cited: 33
Hypophosphataemia, fibroblast growth factor 23 and third-generation intravenous iron compounds: a narrative review
Xenophon Kassianides, Sunil Bhandari
Drugs in Context (2021) Vol. 10, pp. 1-29
Open Access | Times Cited: 31
Anemia in Chronic Renal Disease
Larry A. Greenbaum
Springer eBooks (2023), pp. 1603-1630
Closed Access | Times Cited: 12
Intravenous iron in chronic kidney disease without anaemia but iron deficiency: A scoping review
Abdulrahman Alsunaid, Sebastian Spencer, Sunil Bhandari
World Journal of Nephrology (2025) Vol. 14, Iss. 1
Closed Access
Conventional and complementary alternative medicine therapies for renal anemia: a literature review
C C Lu, Yuan-Hsuan Hsu, I-Hsin Lin, et al.
Frontiers in Endocrinology (2025) Vol. 15
Open Access
Iron in Chronic Kidney Disease and End-Stage Kidney Disease—Current Trends and Future Direction
Thomas McDonnell, Philip A. Kalra
British Journal of Hospital Medicine (2025), pp. 1-19
Closed Access
Iron deficiency anemia in patients with heavy menstrual bleeding: The patients’ perspective from diagnosis to treatment
Imo J. Akpan, Mohit Narang, Edio Zampaglione, et al.
Women s Health (2025) Vol. 21
Open Access
Understanding and Managing Infusion Reactions and Hypophosphataemia With Intravenous Iron—A Nurses' Consensus Paper
Aileen Fraser, V Cairnes, Edwin J. Mikkelsen, et al.
Nursing Open (2025) Vol. 12, Iss. 4
Open Access
Anämien
Jan Matthes
Springer eBooks (2025), pp. 235-245
Closed Access
Improving the safety of intravenous iron treatments for patients with chronic kidney disease
Xenophon Kassianides, Adil M. Hazara, Sunil Bhandari
Expert Opinion on Drug Safety (2020) Vol. 20, Iss. 1, pp. 23-35
Closed Access | Times Cited: 27
Comparative Risk of Hypophosphatemia Following the Administration of Intravenous Iron Formulations: A Network Meta-Analysis
Ioannis Bellos, Maximos Frountzas, Vasilios Pergialiotis
Transfusion Medicine Reviews (2020) Vol. 34, Iss. 3, pp. 188-194
Closed Access | Times Cited: 26
Intravenous ferric derisomaltose for the treatment of iron deficiency anemia
Michael Auerbach, David H. Henry, Thomas G. DeLoughery
American Journal of Hematology (2021) Vol. 96, Iss. 6, pp. 727-734
Open Access | Times Cited: 22
Safety and Efficacy of Intravenous Ferric Derisomaltose Compared to Iron Sucrose for Iron Deficiency Anemia in Patients with Chronic Kidney Disease With and Without Heart Failure
Andrew P. Ambrosy, Stephan von Haehling, Paul R. Kalra, et al.
The American Journal of Cardiology (2021) Vol. 152, pp. 138-145
Open Access | Times Cited: 21
Intravenous ferric derisomaltose versus saccharated ferric oxide for iron deficiency anemia associated with menorrhagia: a randomized, open-label, active-controlled, noninferiority study
Hiroshi Kawabata, Takeshi Tamura, Soichiro Tamai, et al.
International Journal of Hematology (2022) Vol. 116, Iss. 5, pp. 647-658
Open Access | Times Cited: 15
Page 1 - Next Page

Scroll to top